Rigel Pharmaceuticals (RIGL) EBIAT (2016 - 2025)
Historic EBIAT for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.9 million.
- Rigel Pharmaceuticals' EBIAT rose 12461.96% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 281935.07%. This contributed to the annual value of $17.5 million for FY2024, which is 16968.63% up from last year.
- Rigel Pharmaceuticals' EBIAT amounted to $27.9 million in Q3 2025, which was up 12461.96% from $59.6 million recorded in Q2 2025.
- In the past 5 years, Rigel Pharmaceuticals' EBIAT ranged from a high of $59.6 million in Q2 2025 and a low of -$27.4 million during Q1 2022
- In the last 5 years, Rigel Pharmaceuticals' EBIAT had a median value of -$5.7 million in 2023 and averaged $782421.1.
- As far as peak fluctuations go, Rigel Pharmaceuticals' EBIAT plummeted by 16948.1% in 2022, and later skyrocketed by 588766.99% in 2025.
- Quarter analysis of 5 years shows Rigel Pharmaceuticals' EBIAT stood at -$22.6 million in 2021, then soared by 106.19% to $1.4 million in 2022, then plummeted by 47.39% to $737000.0 in 2023, then surged by 1845.86% to $14.3 million in 2024, then surged by 94.55% to $27.9 million in 2025.
- Its EBIAT was $27.9 million in Q3 2025, compared to $59.6 million in Q2 2025 and $11.4 million in Q1 2025.